

## CURRICULUM VITAE

Devalingam Mahalingam, MD, PhD

**Home address:** 2342 Fountain Way  
San Antonio, TX 78248

**Office address:** Cancer Therapy and Research Center  
7979 Wurzbach Road  
Mail Code 8232  
San Antonio, TX 78229  
(210) 450-5970  
(210) 450-1686  
[mahalingam@uthscsa.edu](mailto:mahalingam@uthscsa.edu)

**Birthdate:** 11/4/1975

**Education:** 2009 - PhD- Cancer Research. Dept. of Medicine  
National University of Ireland,  
Galway, Ireland

2000 - MB BCh BAO Medicine  
National University of Ireland,  
Galway, Ireland

**Postgraduate education:** 2001-2003 –Medicine Residency  
Royal College of Medicine Ireland,  
Dublin, Ireland

2004-2009 -Medical -Higher Specialty in Medical Oncology,  
Royal College of Physicians Ireland,  
Dublin, Ireland

2008-2009 -Medicine- Oncology Fellowship  
Institute of Drug Development, UTHSCSA,  
San Antonio, TX, USA

**Licensure:** Texas Medical Board -2009 to date.  
Permanent License 2012 – to date P1668  
Temporary Medical License 2011 -43610  
Temporary Medical License 2010 - 43148  
Temporary Medical License 2009- 42669

**Certification:** American Board of Internal Medicine (ABIM)-08/2013-354753  
ABIM Medical Oncology-11/2014-354753  
Specialty Registration Medical Oncology - Royal College of Physicians of  
Ireland-06/2011 to date  
Royal College of Physicians United Kingdom (Internal Medicine)-03/2003  
Royal College of Physicians of Ireland (Internal Medicine)-02/2003  
ACLS - ACLS - Certified -09/2015 - to date

United States Medical Licensing Exams - USMLE Step 2 CS-12/2007  
United States Medical Licensing Exams - USMLE Part 1-10/2007

**Awards:** 09/2013-Texas Society of Clinical Oncology (TxSCO) Fellows Award:  
Mentored Sukeshi Patel (recipient)  
11/2012-Student Research Competition and the Dean James J Young  
Award: Medical student Jamie Pinckard (recipient)  
10/2012-Key to the Cure Award  
12/2011-CTRC Clinical Investigator of the year  
10/2009- Southwest Oncology Group Meeting, New Investigator Award  
06/2009-FECS/AACR/ASCO Methods in Cancer Biology Award  
06/2008-FECS/AACR/ASCO joint "Methods in Clinical Cancer Research"  
03/2007-Oncology Scholar Travel Award  
01/2005-4<sup>th</sup> Masterclass in Oncology: European School of Oncology.  
12/2001-Annual Case Presentation Competition JCMH, Dublin.  
06/1997-Health Research Board (HRB) Ireland, Medical student award.

**Professional Experience:** 09/2014 to date: Associate Professor  
Division of Hematology/Oncology  
Department of Medicine,  
University of Texas Health Science Center, San Antonio.

2011-Leader Gastrointestinal Malignancies Program &  
Co-Leader GU malignancies program, UT Health Science Center  
Cancer Therapy and Research Center, San Antonio, TX

09/2009 - 08/2014 -Assistant Professor of Medicine --UT Health Science  
Center at Cancer Therapy and Research Center, San Antonio, TX

Staff physician  
2009 to date: University Health Care system  
2014 to date: St. Luke's Baptist Health System

**Professional Organizations:** Southwest Oncology Group (SWOG)- GI & GU committee  
American Association of Cancer Research  
American Society of Clinical Oncology  
Royal College of Physicians of United Kingdom  
Royal College of Physicians of Ireland

**Activities:** 2011-to date -Leader Gastrointestinal Malignancies, UTHSCSA  
2010-2015 Co-leader GU malignancies, UTHSCSA  
2010- IIMS/CTSA Pilot Project Scientific Review Panel  
2010-CTRC clinical trial pilot grant-Internal Reviewer  
2015- British Journal of Cancer- Journal Reviewer  
2009--Molecular Cancer Therapeutics --Journal Reviewer  
2009--Targeted Oncology --Journal Reviewer  
2009--Expert Opinion Journal series --Journal Reviewer  
2009--Cancer Chemotherapy and Pharmacology --Journal Reviewer  
2009-2013 Protocol Review Committee, UT Health Science Center  
2009-Present--Data Safety and Review Committee, UT Health Science

## Presentations:

07/2015-Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN, ESMO 17th World GI Cancer 2015 Conference, European Society for Medical Oncology World 2015, Barcelona, Spain.

07/2015-Treatment Innovations for Advanced Prostate Cancer, CTRC Community Cancer Seminar, San Antonio, TX

06/2015-PREVENTION OF NEUROPATHY USING CALMANGAFODIPIR, MASCC/ISOO 2015, Bone and neurological complications and nausea and vomiting, PledPharma AB, Copenhagen, Denmark (Oral Presenter)

06/2015-First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors, ASCO 2015-51st Annual Meeting, Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics, American Society of Clinical Oncology, Chicago, IL (Poster Discussion session)

05/2015-A mass spectrometry based serum test for the detection of HCC, AACR 2015 Annual Meeting, Cancer Researchers, American Association of Cancer Research, Philadelphia, PA

03/2015-Hepatocellular carcinoma research/clinical care, UT System Hepatocellular Carcinoma Cancer Symposium, University of TX, Ausitn, TX (Panel)

01/2015- Clinical activity and correlative DCE-MRI imaging of G-202, a thapsigargin-based prostate-specific membrane antigen-activated prodrug, 2015 GI Cancers Symposium, Gastrointestinal Cancers, ASCO, San Francisco, CA

09/2014-Metformin in combo w/ castration therapy in Prostate Canc, AACR Metformin in clinical trials special workshop, Clinical Investigators, American Association of Cancer Research, New Orleans, LA.

02/2014-Therapeutic Advances in the Management of Advanced HCC, Practical Applications of New Agents in Oncology, Oncology, UTHSCSA, San Antonio, TX (Oral presentation)

10/2013-A First-in-Human, Phase I Clinical Study of G-202, a Thapsigargin-Based Prostate-Specific Membrane Antigen (PSMA)-Activated Prodrug, in Patients with Advanced Solid Tumors, EORTC-NCI-AACR Symposium, Medical Oncologists, UTHSCSA, Boston, MA

06/2013-Beyond VEGF inhibition: Comparative efficacy analysis of novel VEGF and non-VEGF therapeutic agents in phase I trials for patients with metastatic colorectal cancer (mCRC)., American Society of Clinical Oncology (ASCO), Colorectal cancer, Chicago, IL

06/2013-A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors, American Society of Clinical Oncology (ASCO), Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics, Chicago.

11/2012-Inhibition of Autophagy: A Phase 1 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic analysis of Hydroxychloroquine in combination with the HDAC inhibitor, Vorinostat, in patients with advanced solid tumors, EORTC-NCI-AACR, Clinical therapeutics, Dublin, Ireland

11/2012-A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors, EORTC-NCI-AACR, Clinical Therapeutics, Dublin, Ireland

11/2012-A Study of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma, EORTC-AACR-NCI, Clinical Therapeutics, Dublin, Ireland

11/2012-Pharmacokinetic Study of Enzastaurin in Cancer Patients with Varying Degrees of Hepatic Dysfunction, EORTC-NCI-AACR, Clinical Therapeutics, Dublin, Ireland

06/2012-Modulation of autophagy: Phase 1 Safety, Tolerability, and Pharmacokinetics (PK) of Hydroxychloroquine (H) in Combination with the HDAC inhibitor Vorinostat (V) in Patients with Advanced Solid Tumors., American Society of Clinical Oncology (ASCO), Early Therapeutics, Chicago

06/2012-Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutics committee study., American Society of Clinical Oncology (ASCO), Developmental Therapeutics - Experimental Therapeutics, Chicago, IL

05/2012-GE junction cancers- Treatment update, 15th Annual Cancer Updates: Doctors Hospital Laredo., Laredo, TX (Invited Speaker)

11/2011-Phase 1 Pharmacokinetics (PK) Assessments of ATI-1123, a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation, in Patients with Advanced Solid Malignancies, EORTC-NCI-AACR, San Francisco, CA

09/2011-Current treatment advances in Gastric cancers, Fellows Conference, UTHSCSA, San Antonio, TX (Invited Speaker)

06/2011-MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules, American Society of Clinical Oncology, Developmental Therapeutics - Experimental Therapeutics, Chicago, IL

06/2011-Phase I study evaluating the pharmacokinetics (PK) of components of S-1 in patients with impaired hepatic function, American Society of Clinical Oncology, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy, Chicago, IL

04/2011-Inhibition of the Hedgehog Signaling Pathway has significant pre-clinical activity and prevents development of Androgen-Independent Prostate Cancer, American Association of Cancer Research (AACR), Orlando, FL

01/2011-Phase 1 Pharmacokinetic (PK) Assessments of ATI-1123, a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation, in Patients with Advanced Solid Malignancies, American Society of Clinical Oncology (ASCO), Chicago, IL

11/2010-Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma., EORTC-NCI-AACR, Melanoma, Berlin, Germany

06/2010-Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors., American Society of Clinical Oncology (ASCO), Chicago, IL

06/2010-Mammalian target of rapamycin (mTOR)-induced pneumonitis: Single-institution experience and treatment., American Society of Clinical Oncology (ASCO), Chicago, IL

06/2010-A New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Superior Specimens with Less Pain: Results of a Randomized Clinical Study, American Society of Hematology 2010, Atlanta, GA

02/2010-A Novel First in Class Inhibitor of the NEDD8 Activating Enzyme (NAE), has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia (AML), Fifth International Conference SUMO, MD Anderson Cancer Center, Houston, TX

01/2010-The First-In-Class Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), MLN4924, Induces Stable Disease Regression in Pre-Clinical Models of Acute Myeloid Leukemia (AML), European Hematology Association

11/2009-SGI-1776: A novel PIM kinase inhibitor with potent preclinical activity against acute myeloid leukemia, AACR-EORTC-NCI

06/2009-A Novel First in Class Inhibitor of the NEDD8 Activating Enzyme (NAE), has Potent Activity in Pre-Clinical Models of Acute Myeloid Leukemia (AML), European Hematology Association (EHA) 2009, Berlin, Germany

01/2009-The novel PIM kinase inhibitor SGI-1776 significantly enhances pre-clinical activity of sunitinib in renal cell carcinoma, AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, AACR-EORTC-NCI, Boston, MA

01/2009-Vorinostat significantly improves the anticancer activity of temsirolimus in renal cancer through suppression of survivin levels, Annual Conference, American Association of Cancer Research, Denver, CO

01/2009-A novel first in class inhibitor of the NEDD8 activating enzyme (NAE), has potent activity in pre-clinical models of acute myeloid leukemia (AML), European Hematology Association

01/2009-The Aurora A kinase inhibitor MLN8237 targets Aurora A kinase and BCR-ABL kinase in CML, is effective in Imatinib resistant T315I mutations, and significantly increases the efficacy of Nilotinib, American Association of Cancer Research (AACR), AACR

01/2009-The Aurora A kinase inhibitor MLN8237 targets Aurora A kinase and BCR-ABL kinase in CML, is effective in Imatinib resistant T315I mutations, and significantly increases the efficacy of Nilotinib, European Hematology Association, EHA

01/2009-The Aurora A kinase inhibitor MLN8237 targets Aurora A kinase in AML, and significantly increases the efficacy of the standard of care agent Cytarabine, European Hematology Association, EHA

01/2009-SGI-1776: A novel PIM kinase inhibitor with potent preclinical activity against acute myeloid leukemia, European Hematology Association, EHA

12/2008-DR5 selective TRAIL variants induce efficient cell death in tumor cells, Irish Society of Medical Oncology, Irish Society of Medical Oncology

01/2008-A kinase inhibitor MLN8237 has potent anticancer activity in CML and Ph+ ALL models and significantly increases the efficacy of Nilotinib, American Society of Hematology

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.